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Background: It is important to maintain the adequate level of vitamin B6 to ensure stable metabolism. Vitamin B6 serum 
level might decreased by absorption disturbance or increasing demand. Valproic acid increase the synthesis of serum 
GABAergic in the other hand vitamin B6 is required as cofactor for gamma-amino butyric acid (GABA) formation. The 
dosage and duration of valproic acid therapy might be correlated with vitamin B6 serum level. The aim of this study is to 
know the correlation between vitamin B6 serum level against dosage and duration of valproic acid therapy in children with 
epilepsy.
Materials and Methods: This is a cross sectional study to investigate the correlation between vitamin B6 serum level 
against dosage and duration of valproic acid therapy. The level of vitamin B6 serum was determined by checking vitamin B6 
active form in serum, pyridoxal 5’-phospate (PLP).
Results: In this study, 37 epilepsy children with valproic acid duration therapy more than 3 months was enrolled. Fifty six 
percent epilepsy children were male, commonly on children age 1-5 years old. Spearman correlation coefficient test showed 
a significant weak negative correlation between vitamin B6 serum level and dosage of valproic acid (r=–0.35; p=0.03), and 
very weak negative correlation with valproic acid duration therapy (r=-0.08; p=0.59), however it was not significant. 
Conclusion: There was a significant weak negative correlation between vitamin B6 serum level and very weak negative 
correlation with valproic acid duration therapy, but not significant in children with epilepsy.
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Introduction
There is some role of Vitamin B6 in various metabolisms 
of multiple enzymes which is important to maintain the 
adequate level of vitamin B6 serum. The abundant of 
availability food-rich vitamin B6 in developing countries 
make the incident of deficiency of vitamin B6 due to low 
intake is less frequent.1 However, certain conditions can 
decrease the level of vitamin B6.
 Many literatures has reported about the low level of 
vitamin B6 in the usage of anti-epileptic drugs.2,3,4  Anti-
epileptic drugs (AED) is thought to reduce the level of 
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vitamin B6 serum, presumably because most of antiepileptic 
drugs act as direct enzyme inducers which can modulate 
the activity of enzymes in liver.4 Induction metabolism of 
those enzymes can cause depletion of involving cofactor 
such as vitamin B6, folic acid and vitamin B12.4 The liver 
enzymes reaction which involved the vitamin B6 (pyridoxal 
5'-phosphate) are aspartate aminotransferase and alanine 
aminotransferase.
 The level of vitamin B6 serum can be determined 
quantitatively using levels of pyridoxal 5-phosphate (PLP) 
as one of the active vitamin B6 (vitamer) form which 
is circulating in the blood. PLP level can be detected in 
plasma, serum and cerebrospinal fluid. Previous studies 
showed that the mean PLP plasma level of epileptic children 
decreased significantly after 20 weeks of anticonvulsant 
administration.3 More than 50% of epileptic children treated 
with both valproic acid and carbamazepine were found with 
plasma PLP levels <30 nmol/L (below the normal value 
limit).2 Sener, et al., has found that the mean level of vitamin 
B6 was lower in the AED group than in non-AED group.4 
Valproic acid is one of the most widely used AED in current 
management of epilepsy in children because it is the first 
choice agent for most types of epilepsy, both symptomatic 
and idiopathic.5 Unlike other types of AED, valproic acid 
is not inducer enzyme.5 However valproic acid works by 
increasing the synthesis of GABAergic in which vitamin B6 
acts as cofactor in the formation of am-aminobutyric acid 
(GABA). The increment synthesis of GABA, increases the 
demand of vitamin B6 and may affect the level of vitamin 
B6 in blood. In this study we want to know whether valproic 
acid correlates with the level of vitamin B6 in serum. In 
order to know it, this study was conducted to determine 
the correlation between vitamin B6 against dosage and the 
duration of valproic acid usage.
Materials and methods
The design of this study was cross-sectional, conducted 
from June 2017 to January 2018. This is the first study 
which was correlated PLP levels with doses of valproic acid 
in the particular population of children. The current fact 
is AED an enzyme inducer which can decreases the PLP 
levels. However, in the other hand valproate acid is not an 
enzyme inducer. The study sample was epileptic children 
whom treated in Sanglah Hospital and received valproic 
acid therapy more than 3 months, due to the average AED 
therapy dose can be achieved within 3 months of the initial 
therapy. Clinical indication of vitamin B6 examination is 
that if there is a downward trend it is necessary to consider 
vitamin B6 supplementation when administering valproic 
acid.
 This is a correlation study, this result cannot be 
implemented yet, however, it has been able to raise the 
issue that vitamin B6 not only decreases due to AED which 
are an enzyme inducers, but also by non-inducer enzymes. 
Based on the vitamin B6 insert kit we used, the results of 
this examination cannot be used to diagnose but only for 
research, so the vitamin B6 levels that we get cannot be 
categorized as low, normal, or high. However the data on 
vitamin B6 levels will be useful if we do a comparison/
relationship analysis. 
 Exclusion criteria included epileptic children 
with severe infections, Crohn's disease, consume INH, 
malnutrition, impaired kidney function and liver function, 
had vitamin B6 supplementation in the last 2 months. 
Sample was collected consecutively.
 Nutritional status was determined when the patient 
became a sample by measuring body length in cm and 
weighing body weight (BW) expressed in kg, ideal BW 
determined based on body lenght plotted on the CDC 
curve for ages > 5 years and WHO curve for age ≤ 5 
years. Nutritional status is determined based on the actual 
percentage of BW / ideal BW which is categorized as obese 
> 120%, overweight > 110 - 120%, well nourish 90 - 110%, 
malnutrition < 90%.
 The minimum sample size is calculated based on the 
calculation of single sample size with correlation coefficient 
was set at 0.410.4 The determination α 0.05 and β is set at 
80%, so the minimum sample size was 20.
 Data including identity, age, gender, body weight, 
height, and clinical variables (such as onset of epilepsy, 
history of febrile seizures or epilepsy in family, type of 
epilepsy, the dosage of valproic acid, duration of valproic 
acid) were recorded from eligible samples. Epilepsy onset 
is the age at the first time diagnosed with epilepsy as noted 
in the medical record, expressed in months. History of 
epilepsy and/or febrile seizures in the family, stated "Yes" 
if in one generation level (first degree relatives) the family 
has a history of epilepsy or febrile seizures in the family, 
otherwise stated "No". The duration of administration of 
valproic acid is the time period when the patient begins to 
receive epilepsy with valproic acid (monotherapy) until it 
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is sampled, expressed in months. The type of seizure is a 
general or focal type of seizure according to the diagnosis 
in the medical record or that has been adjusted to the 
EEG results. The dose of valproic acid is the total dose of 
valproic acid in milligrams consumed by the patient in a 
day divided by the body weight of the patient when used as 
a case expressed in mg/kgBW/day. 
 After recording, 3 mL of blood was drawn by 
laboratory officer. Blood samples were taken with a clear 
red lid tube with no carbon-covered anticoagulant (plain 
tube), centrifuged as soon as the sample was received to 
get the serum.  Serum  stored   in  opaque  plastic  none 
translucent and stored in frozen conditions at a temperature 
of -40°C. Serum  storage  in  our  study  follows  the 
procedure  applicable  in the Sanglah Hospital clinical 
pathology laboratory.
 In  principle, the serum must be stored at a 
temperature of no more than -20°C, PLP is stable in the 
refrigator for up to 5 years at -70°C. After all samples were 
collected, vitamin B6 was examined at once. Vitamin B6 
serum level was expressed by the level of PLP in unit of 
picomol/liter. Examination techniques using enzyme-
linked immunosorbent assay (ELISA) using reagents from 
BioAssay Technology Laboratory-Human Vitamin B6 
ELISA  Kit.  Elisa  sandwich  method  is  cheaper  than high 
performance liquid chromatography (HPLC). 
 Statistical analysis was performed using computer 
(SPSS.20). The data distribution was analyzed by Shapiro-
Wilk test and categorized as normal distribution if p-value 
more than 0.05. Correlation test for PLP level, drug dosage 
and duration of valproic acid were analyzed by Spearman 
test. Informed consent was made to the parents of subjects 
who met the inclusion and exclusion criteria. Blood 
collection and data were carried out after informed consent 
was signed. This research has been approved by Research 
Ethics Commission, Faculty of Medicine, Udayana 
University with protocol study number: 1389/UN14.2.2/
PD/KEP/2018. 
Results
This study involved 37 epileptic children whom were treated 
with valproic acid. Normality test by Shapiro-Wilk on PLP 
level, dosage of valproic acid and duration of valproic acid 
usage showed that the data were not distributed normally, 
while data of age were distributed normally. Onset of 
epilepsy, nutritional status, and duration of treatment 
are displayed in ordinal variables. Table 1 shows the 
characteristics of subjects.
 The mean age of this study was 5.5 years, and 22 
(59.5%) was male. The onset of epilepsy mostly (57%) 
started at the age of 1-5 years. Twenty-seven percent of 
subjects had history of febrile seizures and or epilepsy in 
family. Approximately 59.5% of epilepsy subjects were 
well-nourished, the remaining 22% were undernourished, 
13.5% obese, and 5.4% more nutrition. The distribution of 
PLP levels in this research vary widely with middle value 
was 325 pmol/L and ranged from 67.9 to 1902.6 pmol/L. 
Four from five obese subjects had PLP level below the 
median (<325 pmol / L), meanwhile 1 obese subject with 
PLP value 325 pmol/L. While the remaining had various 
value. Types of epilepsy based on seizure type and etiology 
showed 59.5% were idiopathic epilepsy and 86.5% with 
general epilepsy manifestation.
 The three variables (PLP level, valproic acid dosage, 
duration of valproic acid) that would be tested by the 
hypothesis were numerical variables with non normal 
distribution. 
 Based on the Spearman correlation test, there was a 
significant weak negative correlation between PLP serum 
level and dosage of valproic acid, and there was a very weak 
negative correlation between PLP serum level and duration 
of valproic acid usage but the correlation was not significant 
(Table 2).
Discussion
Vitamin B6 is a water soluble vitamin which is found in 
many foods. Vitamin B6 involves in metabolism of proteins, 
carbohydrate and fat in body. The involvement of vitamin 
B6 in the reaction is closely related to the function of the 
nervous system, immune system and endocrine.2,6 PLP is 
one of the active forms of vitamin B6 which acts as cofactor 
in glutamate acid decarboxylase reaction by changing 
glutamate into GABA.7,8 Thus, considering the vital role 
of vitamin B6 in body metabolism, deficiency of vitamin 
B6 could affect body metabolism reaction. Valproic acid as 
the most widely used antiepileptic drug today was showed 
by several studies can decrease vitamin B6 level in subjects 
whom use valproic acid.
 Our research subjects were epilepsy patients with 
average  of  5.5  years  old.  Fifty-nine  percent  of  them 
were male. This incidence was more frequent in males, in 
accordance with previous study, in which 56.9% of epileptic 
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Unit Value
n (%) 22 (59.5)
median (minimum–maximum) 24 (1–110)
mean (SD) 65.9 (37.3)
n (%) 10 (27)
Obese, n (%) 5 (13.5)
Overweight n (%) 2 (5.4)
Well nourished n (%) 22 (59.5)
Malnutrition n (%) 8 (22)
median (minimum–maximum) 325 (67.9–1902.6)
median (minimum–maximum) 20 (15–40)
< 20 months n (%) 23 (62.2)
≥ 20 months n (%)  14 (37.8)
n (%) 32 (86.5)
n (%) 22 (59.5)
(n = 37)
PLP, pmol/L
Valproic acid dosage, mg/kg/day
Duration of Valproic acid, months
Epilepsy type general seizure
Idiopathic epilepsy
Study characteristics
Gender, male 
Onset of epilepsy, months old
Age, months old
Has family history of febrile seizure or epilepsy
Nutritional status
Table 1. Characteristics of of epileptic children whom received valproic acid. 
pmol/L: picomol per liter; mg/kg/day: milligram/kilogram/day; SD: standard deviation.
patients were males.9 Onset of epilepsy commonly started in 
ages 1 to  5 years old. This result was different from previous 
study which showed epilepsy onset below 1 year old.9 This 
is likely due to the different inclusion and exclusion criteria 
of this study. Subjects with history of febrile seizures and 
epilepsy in our study was 27%. Previous studies found 
10% of patients with history of febrile seizures in family, 
and 13% with family history of epilepsy.9 A study in Turkey 
also found similar result, there was history of first degree 
relative (16%), second degree relative (6%), and third 
degree relative (2.5%).10 Similar to previous studies, the 
subjects’ nutritional status of this study were dominated 
by well nourish 57.5%, followed by malnutrition 22% and 
obese 13.5%. Previous studies found 69.9% well nourish, 
21% undernourished, 6% obese.9 General epilepsy was 
found in 85.4% and 58.5% was idiopathic epilepsy. Similar 
to previous study 80.4% had general seizures, idiopathic 
epilepsy 74.5%.9
 PLP level in serum or plasma is generally used to assess 
vitamin B6 status. Vitamin B6 level was said to sufficient 
at level of 20 nmol/L, and sub-optimal when plasma PLP 
level are 10 nmol/L.11 However, many literatures and 
studies have different cut off points, which is categorized 
to be normal if PLP level in serum or plasma >30 nmol/L, 
and deficiency if the level is  below 20 nmol/L.2-4,7,10,12 
Based on the recommended dietary allowance (RDA) to 
maintain adequate level of vitamin B6 in body, daily intake 
of vitamin B6 1.5-2 mg is highly required.13 Vitamin B6 has 
low toxicity, neuropathy symptoms will only appear in a 
dosage 1000 mg/day of vitamin B6.14
 Meassurement of vitamin B6 level can be done by 
several methods, such as spectrometry, chromatography, 
electrochemistry and enzymatic assay.15 Nowadays the 
diagnostic test using a HPLC method which result PLP level 
in international units nmol/L. In this study, researchers used 
sandwich ELISA as one of the enzymatic assay methods. 
This method is able to detect vitamin B6 in both serum and 
plasma with sensitivity up to 2.51 pmol/L (standard curve 
range 5-1500 pmol/L). PLP level from the results cannot be 
interpreted into deficiency or normal status.
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Valproic acid dosage r -  0.35
p 0.03
Duration of valproic acid r - 0.08
p 0.59
PLP level
Table 2. Spearman correlation test results.
 In this study, the PLP level of subjects ranged from 
67.9 to 1902.6 pmol/L with a median level of 325 pmol/L. 
It was interesting finding in the distribution of PLP level 
from 4 out of 5 obese subjects whose PLP level below the 
median (<325 pmol/L), 1 obese subject with PLP values 325 
pmol/L. While the other nutritional status were found vary. 
This is probably related to the chronic inflammation process 
that occurs in obese patients. However, this condition was 
not discussed in this study.
 Previous study found that the average PLP plasma 
concentration decreased below normal values (>30 nmol/L) 
in 70% of patients with phenytoin, and more than 50% 
of patients with both valproic acid and carbamazepin and 
22% of patients with lamotrigine, but it did not showed 
meaningful differences between those 4 groups.2 In several 
correlation studies there was no significant correlation 
between the duration of valproic acid therapy with PLP 
level.4,14 The median PLP value in this study was 325 
pmol/L. Eighteen subjects (48.6%) were obtained with 
PLP levels <325 pmol/L where 61% were experienced by 
subjects with as valproate dosage ≥25 mg/kg/day. We do not 
know yet what dose of valproic acid is. 
 The results showed a significant negative correlation 
between vitamin B6 levels and the dose of valproic acid, 
the higher the dose the lower the vitamin B6. These results 
indicate a tendency to decrease due to valproate, a clinical 
implication considering the administration of vitamin B6 
in epilepsy patients who get valproic acid. Further research 
is needed with different designs to prove the relationship 
between the two variables. The fact that there is currently is 
OAE enzyme inducer decreases PLP levels. But valproate 
acid is not an enzyme inducer. There have been no studies 
that have correlated PLP levels with doses of valproic acid 
in the particular population of children. In another study, 
it was stated that 50% of epilepsy patients experienced 
a decrease in PLP but not specifically mentioned the 
percentage decrease in users of valproate acid. Only 50% 
was mentioned in patients with val and carbamazepine, and 
no correlation was conducted in the study.2
           Our study found a weak significant negative correlation, 
r=-0.35; p=0.03, although it was weak in correlation, this 
result indicate the possibility of the higher dosage of valproic 
acid, the lower the plasma PLP level. Previous research by 
Sener, et al., stated that the mean of vitamin B6 level in 
the AED group was lower than non-AED group, but there 
was no significant difference in the average PLP in the two 
groups. Significant difference was found only in patients 
using carbamazepin which showed decrease tendency.4 This 
result was differ from our study’s result, probably caused by 
different hypothesis test. Correlation study by Davis, et al., 
found 37% epilepsy children had vitamin B6 level below the 
lowest limit of reference range and did not find relationship 
between decreased level of vitamin and anticonvulsants 
both monotherapy and polytherapy.11 These results were 
contradiction with our results. AED in the study of Davis, 
et al., was more diverse. In addition, there was difference 
of age between previous studies and this study, which the 
age of subjects in previous study was older than 10 years 
old.11 However,  in this study, the mean age of subjects was 
5.5 years old.
 Valproic acid works by enhancing the GABAergic 
system by increasing GABA synthesis.16 This condition 
make a possibility that the higher the dose, the higher demand 
for vitamin B6 will be needed, which will decrease the level 
of PLP. Other drugs that have similar effect to valproic acid 
are benzodiazepine, tiagabine, vigabatrin, gabapentin, but 
all four drugs are GABAergic via different mechanism. 
Benzodiazepine works by increasing the function of GABA 
receptors, tiagabine and vigabatrin decreases GABA 
degradation and GABA reuptake, gabapentin increases 
GABA release through unclear mechanisms, although it is 
thought it can increase GABA synthesis, but some literature 
consistently stated only valproic acid which works by 
increasing GABA synthesis.16
 This study found that 80.5% subjects have long 
duration of valproic acid usage more than 24 months. 
In the Spearman test, there was no correlation between 
vitamin B6 level and the duration of valproic acid usage 
(r=-0.08; p=0.59). Similar to previous studies that found no 
correlation between the duration of anti-epileptic drugs with 
vitamin B6, homocysteine, and vitamin B12.4 Similarly 
with previous study, there was no correlation between the 
duration of valproic acid therapy.
 47
Correlation of PLP Level and Valproic Acid Suwarba IGNM, et al.
 The best measurement of vitamin B6 level can be 
obtained by combining other biomarkers such as: alkaline 
phosphatase (ALP), low albumin serum level, renal 
function and inorganic phosphate. The weakness of this 
study is we did not combine the vitamin B6 level with other 
inflammatory markers due to limited funding. 
Conclusion
There is a significant weak correlation between vitamin 
B6 level with dosage of vaproat acid and weak negative 
correlation that was not significant between vitamin B6 
level and the duration of valproic acid usage. 
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